- Home
- AUPH vs OCS Comparison
AUPH vs OCS Comparison
Compare AUPH & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | OCS |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | Canada | Switzerland |
| Employees | N/A | 60 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUPH | OCS |
|---|---|---|
| Price | $15.44 | $11.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $17.25 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 1.4M | 358.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $17.54 | $466.06 |
| Revenue Next Year | $15.74 | $479.73 |
| P/E Ratio | $61.40 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $8.80 | $10.52 |
| 52 Week High | $19.25 | $34.48 |
Technical Indicators
Market Signals| Indicator | AUPH | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 30.55 |
| Support Level | $15.43 | $10.52 |
| Resistance Level | $16.38 | $21.79 |
| Average True Range (ATR) | 0.55 | 0.68 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 29.59 | 8.97 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.